Workshop on good clinical practices in clinical trials and post-marketing surveillance
Other Titlesa report
AbstractThe WHO South-East Asia Region (SEAR) is emerging as a major producer and supplier of vaccines to the global and regional markets. India, Indonesia and to some extent Thailand, the three South-East Asia vaccine producing countries, are expected to increasingly take over the supply of traditional EPI vaccines and new combination vaccines to meet the regional and global vaccine demands. At the same time, these countries are investing in the research and development of new vaccines. Vaccine production requires a strong regulatory system to monitor safety, quality and efficacy, and clinical trials during the different phases of vaccine development are important and critical activities. Furthermore, vaccine manufacturers in industrialized countries are increasingly looking at developing countries to conduct clinical trials, to produce or finalize vaccines (filling, packaging) and to distribute vaccines worldwide. Different approaches are taken such as joint ventures and installation of facilities by such manufacturers in developing countries. Joint ventures have already been established in India, Thailand, Indonesia and in Myanmar. In this context, national regulatory authorities (NRAs) in developing countries are faced with the challenge of fully regulating vaccines to ensure their safety, quality and efficacy, including the oversight of clinical trials that may be conducted. Developing countries are expected to establish accredited scientific and technical review committees as well as research ethics committees to ensure compliance with principles of Good Clinical Practice (GCP) consistent with international ethics norms and a monitoring system for Adverse Events Following Immunization (AEFI) in the post-licensing era of vaccine. While some Member Countries in the Region have developed capacity, most either do not have such regulatory processes in place or there are not often implemented adequately. Therefore, assisting Member Countries in strengthening capacity in this area is a priority activity for IVD.
World Health Organization, Regional Office for South-East Asia. (2007). Workshop on good clinical practices in clinical trials and post-marketing surveillance. WHO Regional Office for South-East Asia. http://www.who.int/iris/handle/10665/206147
Gov't Doc #SEA-Immun-46
MetadataShow full item record
Showing items related by title and MeSH subject.
Integration of HIV and TB services: • a: Does ART provided at the TB clinic result in better outcomes than referring people with TB and HIV for ART in specialized HIV clinics? • b: Does TB diagnosis and/or TB treatment at specialized HIV clinics result in better outcomes than referring people living with HIV to TB clinics for TB diagnosis and/or TB treatment? World Health Organization; University of California, San Francisco (WHO/HIV/2013.82, 2013)
Good clinical diagnostic practice: a guide for clinicians in developing countries to the clinical diagnosis of disease and to making proper use of clinical diagnostic services World Health Organization, Regional Office for the Eastern Mediterranean (2005)Physicians in developing countries usually take a syndromic approach to diagnosing a patient. Today, we observe increasing microbial resistance to drugs, particularly in developing countries. This worsening situation puts a heavy obligation on medical professionals to improve their clinical diagnosis. Clinical diagnostic services provide more accurate information on a patient based on physical and biochemical investigations. However, in many countries there is little communication between the physicians and the laboratory and diagnostic imaging ...
Working Group on Assessment of Clinical Technologies : identification of essential clinical chemical and haematological tests in intermediate hospital laboratories World Health Organization. Health Laboratory Technology Unit (LAB/86.2. Unpublished, 1986)